Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update
TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management's 2026 projection, and...



